Comment on “Massive idiopathic pericardial effusion in a pediatric patient responsive to interleukin-1 receptor antagonist: Unveiling an undercover hyperinflammation?”

Q: What is the clinical evidence from this study?

Study design: Letter. Population: Massive chronic idiopathic pericardial effusion. Intervention: Anakinra.

Dilek Borakay

doi:10.4103/apc.apc_197_26

September 1, 2026Annals of Pediatric CardiologyOpen Access

Comment on “Massive idiopathic pericardial effusion in a pediatric patient responsive to interleukin-1 receptor antagonist: Unveiling an undercover hyperinflammation?”

View Full Paper

Ask AI

Bookmark

Share

Key result

Extrapolating interleukin-1 blockade therapies like anakinra from inflammatory recurrent pericarditis to isolated chronic pericardial effusion requires caution and further phenotype definition.

Key Points

To evaluate the pathophysiological interpretation and clinical rationale for using interleukin-1 receptor antagonist therapy in pediatric massive chronic idiopathic pericardial effusion.
Critical appraisal of a published pediatric case report of massive chronic idiopathic pericardial effusion treated with anakinra.
Analysis of pericardial cytokine dynamics, concurrent colchicine administration, and 2024–2025 ACC and 2025 ESC clinical guidelines on pericardial disease.
Elevated pericardial interleukin-6 (IL-6) reflects local inflammation and increased vascular permeability rather than definitive evidence of primary interleukin-1-driven autoinflammation.
Concurrent administration of colchicine confounds treatment response, precluding definitive attribution of remission solely to interleukin-1 receptor blockade.
International cardiology guidelines position interleukin-1 blockade for refractory recurrent pericarditis with systemic inflammation, warranting caution when extrapolating use to asymptomatic, noninflammatory chronic effusions.

Structured PICO

P

Population

Pediatric patient with massive chronic idiopathic pericardial effusion without overt systemic inflammatory findings

I

Intervention

Anakinra (recombinant IL-1 receptor antagonist) combined with colchicine

Limitations

Elevated IL-6 may be a consequence rather than a reliable upstream marker of IL-1-dominant disease.
Concurrent use of colchicine confounds the interpretation of the sustained remission observed with anakinra.
Patient lacked typical features of active inflammatory pericarditis, challenging the clinical rationale for IL-1 blockade.

Implication

This commentary highlights that while biologic therapy for isolated chronic pericardial effusion is intriguing, extending IL-1 blockade beyond inflammatory recurrent pericarditis warrants caution and adherence to current guidelines.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dilek Borakay (2026) conducted a letter in Massive chronic idiopathic pericardial effusion. Anakinra was evaluated. Extrapolating interleukin-1 blockade therapies like anakinra from inflammatory recurrent pericarditis to isolated chronic pericardial effusion requires caution and further phenotype definition.

synapsesocial.com/papers/6ad1158900741cc3fba7d54d https://doi.org/10.4103/apc.apc_197_26

View Full Paper

Ask AI

Bookmark

Share

Comment on “Massive idiopathic pericardial effusion in a pediatric patient responsive to interleukin-1 receptor antagonist: Unveiling an undercover hyperinflammation?”

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Comment on “Massive idiopathic pericardial effusion in a pediatric patient responsive to interleukin-1 receptor antagonist: Unveiling an undercover hyperinflammation?”

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More from Annals of Pediatric Cardiology

Keep reading

More from Annals of Pediatric Cardiology